Council Regulation (EC) No 111/2005 of 22 December 2004 laying down rules for the monitoring of trade between the Community and third countries in drug precursors
Modified by
- Regulation (EU) No 1259/2013 of the European Parliament and of the Councilof 20 November 2013amending Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the Community and third countries in drug precursors, 32013R1259, December 10, 2013
- Commission Delegated Regulation (EU) 2016/1443of 29 June 2016amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances(Text with EEA relevance), 32016R1443, September 1, 2016
- Commission Delegated Regulation (EU) 2018/729of 26 February 2018amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances(Text with EEA relevance), 32018R0729, May 18, 2018
- Commission Delegated Regulation (EU) 2020/1737of 14 July 2020amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances(Text with EEA relevance)Corrigendum to Commission Delegated Regulation (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances(Official Journal of the European Union L 392 of 23 November 2020), 32020R173732020R1737R(03), November 23, 2020
- Commission Delegated Regulation (EU) 2022/1518of 29 March 2022amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances(Text with EEA relevance), 32022R1518, September 13, 2022
- Commission Delegated Regulation (EU) 2023/196of 25 November 2022amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances(Text with EEA relevance), 32023R0196, January 31, 2023
Corrected by
- Corrigendum to Commission Delegated Regulation (EU) 2020/1737 of 14 July 2020 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances, 32020R1737R(03), August 5, 2021
(a) "scheduled substance" means any substance listed in the Annex that can be used for the illicit manufacture of narcotic drugs or psychotropic substances, including mixtures and natural products containing such substances, but excluding mixtures and natural products which contain scheduled substances and which are compounded in such a way that the scheduled substances cannot be easily used or extracted by readily applicable or economically viable means, medicinal products as defined in point 2 of Article 1 of Directive 2001/83/EC of the European Parliament and of the Council and veterinary medicinal products as defined in point 2 of Article 1 of Directive 2001/82/EC of the European Parliament and of the CouncilDirective 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ L 311, 28.11.2001, p. 67 ). , except medicinal products and veterinary medicinal products listed in the Annex;Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products (OJ L 311, 28.11.2001, p. 1 ).(b) "non-scheduled substance" means any substance which, although not listed in the Annex, is identified as having been used for the illicit manufacture of narcotic drugs or psychotropic substances; (c) "import" means any entry of scheduled substances having the status of non-Union goods into the customs territory of the Union, including temporary storage, the placing in a free zone or free warehouse, the placing under a suspensive procedure and the release for free circulation within the meaning of Council Regulation (EEC) No 2913/92 ;Council Regulation (EEC) No 2913/92 of 12 October 1992 establishing the Community Customs Code (OJ L 302, 19.10.1992, p. 1 ).(d) "export" means any departure of scheduled substances from the customs territory of the Union, including the departure of scheduled substances that requires a customs declaration and the departure of scheduled substances after their storage in a free zone of control type I or free warehouse within the meaning of Regulation (EEC) No 2913/92; (e) "intermediary activities" means any activity to arrange purchase and sale or supply of scheduled substances carried out by any natural or legal person who aims to obtain agreement between two parties or to do so through acting on behalf of at least one of these parties without taking these substances into its possession or taking control of the carrying out of such transaction; this definition shall also include any activity carried out by any natural or legal person established in the Union involving purchase and sale or supply of scheduled substances without these substances being introduced into the customs territory of the Union; (f) "operator" means any natural or legal person engaged in import, export of scheduled substances or intermediary activities relating thereto, including persons pursuing the activity of making customs declarations for clients on a self-employed basis, either as their principal occupation or as a secondary activity related to another occupation; (g) "exporter" means the natural or legal person chiefly responsible for export activities by virtue of the economic and legal relationship to the scheduled substances and to the consignee and, where appropriate, who lodges the customs declaration or on whose behalf the customs declaration is lodged; (h) "importer" means the natural or legal person chiefly responsible for the import activities by virtue of the economic and legal relationship to the scheduled substances and to the consignor and who lodges the customs declaration or on whose behalf the customs declaration is lodged; (i) "ultimate consignee" means any natural or legal person to which the scheduled substances are delivered; this person may be different from the end-user; (j) "natural product" means an organism or a part thereof, in any form, or any substances which occur in nature as defined in point 39 of Article 3 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council ;Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1 ).(k) "International Narcotics Control Board" means the Board established by the Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol.
(a) the name of the scheduled substance as stated in the Annex, or, in the case of a mixture or a natural product, its name and the name of any scheduled substance, as stated in the Annex, contained in the mixture or in the natural product, followed by the term "DRUG PRECURSORS"; (b) the quantity and weight of the scheduled substance and, in the case of a mixture or a natural product, the quantity, weight, and, if available, the percentage of any scheduled substance contained therein; and (c) the names and addresses of the exporter, the importer, the ultimate consignee and, where applicable, the person involved in the intermediary activities.
(a) the name of the scheduled substance; (b) the quantity and weight of the scheduled substance; (c) the names and addresses of the exporter, the importer, the ultimate consignee and, where applicable, the person involved in the intermediary activities.
(a) information on how to identify and notify suspect transactions; (b) a regularly updated list of non-scheduled substances to enable the industry to monitor on a voluntary basis the trade in such substances.
(a) the names and addresses of the exporter, the importer in the third country, any other operator involved in the export operation or shipment, and the ultimate consignee; (b) the name of the scheduled substance as stated in the Annex or, in the case of a mixture or a natural product, its name and eight-digit CN code and the name of any scheduled substance, as stated in the Annex, contained in the mixture or in the natural product; (c) the quantity and weight of the scheduled substance and, in the case of a mixture or a natural product, the quantity, weight, and, if available, the percentage of any scheduled substance contained therein; (d) details of the transport arrangements, such as the expected date of dispatch, method of transport, name of the customs office where the customs declaration is to be made and, where available at this stage, identification of the means of transport, itinerary, expected point of exit from customs territory of the Union and the point of entry into the importing country; (e) in the cases referred to in Article 17, a copy of the import authorisation issued by the country of destination; and (f) the number of the licence or registration referred to in Articles 6 and 7.
(a) details supplied in accordance with Article 13(1) are incomplete; (b) there are reasonable grounds for suspecting that the details supplied in accordance with Article 13(1) are false or incorrect; (c) in the cases referred to in Article 17, it is established that the import of the scheduled substances has not been authorised by the competent authorities of the country of destination, or (d) there are reasonable grounds for suspecting that the substances in question are intended for the illicit manufacture of narcotic drugs or psychotropic substances.
(a) the names and addresses of the importer, the exporter of the third country, any other operator involved and the ultimate consignee; (b) the name of the scheduled substance as stated in the Annex or, in the case of a mixture or a natural product, its name and the eight-digit CN code and the name of any scheduled substance, as stated in the Annex, contained in the mixture or in the natural product; (c) the quantity and weight of the scheduled substance and, in the case of a mixture or a natural product, the quantity, weight, and, if available, the percentage of any scheduled substance contained therein; (d) if available, details of the transport arrangements, such as methods and means of transport, and date and place of envisaged import activities, and (e) the number of the licence or registration referred to in Articles 6 and 7.
(a) details supplied in accordance with Article 21(1) are incomplete; (b) there are reasonable grounds for suspecting that the details supplied in accordance with Article 21(1) in the application are false or incorrect, or (c) there are reasonable grounds for suspecting that the scheduled substances are intended for the illicit manufacture of narcotic drugs or psychotropic substances.
(a) to obtain information on any orders for or operations involving scheduled substances; (b) to enter operators’ business premises in order to obtain evidence of irregularities; (c) to establish that a diversion or attempted diversion of scheduled substances has taken place.
(a) to obtain information on any orders for or operations involving non-scheduled substances; (b) to enter business premises in order to obtain evidence of suspicious transactions involving non-scheduled substances.
(a) to facilitate the communication of information pursuant to Article 32(1) as well as the reporting to the International Narcotics Control Board pursuant to Article 32(3); (b) to manage a European register of operators, which have been granted a licence or registration; (c) to enable operators to provide the competent authorities with information about their export, import or intermediary activities according to Article 9(2), in electronic form.
Substance | CN Code | CAS No | |
---|---|---|---|
1-Phenyl-2-propanone | Phenylacetone | 103-79-7 | |
Diethyl (phenylacetyl) propanedioate (DEPAPD) | 20320-59-6 | ||
Methyl | 16648-44-5 | ||
Ethyl alpha-phenylacetoacetate (EAPA) | 5413-05-8 | ||
80532-66-7 | |||
25547-51-7 | |||
N-acetylanthranilic acid | 2-Acetamidobenzoic acid | 89-52-1 | |
4433-77-6 | |||
4468-48-8 | |||
Isosafrol (cis + trans) | 120-58-1 | ||
3,4-Methylenedioxyphenylpropan-2-one | 1-(1,3-Benzodioxol-5-yl)propan-2-one | 4676-39-5 | |
Piperonal | 120-57-0 | ||
Safrole | 94-59-7 | ||
Ethyl 3-(2H-1,3-benzodioxol-5-yl)-2-methyloxirane-2-carboxylate (PMK ethyl glycidate) | 28578-16-7 | ||
Methyl 3-(1,3-benzodioxol-5-yl)-2-methyloxirane-2-carboxylate (PMK methyl glycidate) | 13605-48-6 | ||
Methyl 3-oxo-2-(3,4-methylenedioxyphenyl)butanoate (MAMDPA) | methyl 3-oxo-2-(3,4-methylenedioxyphenyl)butanoate | 1369021-80-6 | |
3-(1,3-benzodioxol-5-yl)-2-methyloxirane-2-carboxylic acid (PMK glycidic acid) | 2167189-50-4 | ||
N-phenyl-1-(2-phenylethyl)piperidin-4-amine | 4-anilino-N- phenethylpiperidine (ANPP) | 21409-26-7 | |
1-(2-phenylethyl)piperidin-4-one | N-phenethyl-4-piperidone (NPP) | 39742-60-4 | |
N-phenylpiperidin-4-amine (4-AP) | 23056-29-3 | ||
Tert-butyl 4-anilinopiperidine-1-carboxylate (1-boc-4-AP) | 125541-22-2 | ||
N-phenyl-N-(piperidin-4-yl)propanamide (norfentanyl) | 1609-66-1 | ||
Ephedrine | 299-42-3 | ||
Pseudoephedrine | 90-82-4 | ||
Norephedrine | 14838-15-4 | ||
Ergometrine | 60-79-7 | ||
Ergotamine | 113-15-5 | ||
Lysergic acid | 82-58-6 | ||
(1R,2S)-(-)-chloroephedrine | 110925-64-9 | ||
(1S,2R)-(+)-chloroephedrine | 1384199-95-4 | ||
(1S,2S)-(+)-chloropseudoephedrine | 73393-61-0 | ||
(1R,2R)-(-)-chloropseudoephedrine | 771434-80-1 | ||
The stereoisomeric forms of the substances listed in this Category not being cathine | |||
The salts of the substances listed in this Category whenever the existence of such salts is possible and not being the salts of cathine. |
Substance | CN Code | CAS No | |
---|---|---|---|
Red phosphorus | 7723-14-0 | ||
Acetic anhydride | 108-24-7 | ||
Phenylacetic acid | 103-82-2 | ||
Anthranilic acid | 118-92-3 | ||
Piperidine | 110-89-4 | ||
Potassium permanganate | 7722-64-7 | ||
The salts of the substances listed in this Category whenever the existence of such salts is possible. |
Substance | CN Code | CAS No | |
---|---|---|---|
Hydrochloric acid | Hydrogen chloride | 7647-01-0 | |
Sulphuric acid | 7664-93-9 | ||
Toluene | 108-88-3 | ||
Ethyl ether | Diethyl ether | 60-29-7 | |
Acetone | 67-64-1 | ||
Methylethylketone | Butanone | 78-93-3 | |
The salts of the substances listed in this Category whenever the existence of such salts is possible and not being the salts of hydrochloric acid and sulphuric acid. |
Substance | CN designation (if different) | CN Code |
---|---|---|
Medicinal products and veterinary medicinal products containing ephedrine or its salts | Containing ephedrine or its salts | |
Medicinal products and veterinary medicinal products containing pseudo-ephedrine or its salts | Containing pseudoephedrine (INN) or its salts |